Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials. [electronic resource]
Producer: 20210311Description: 898-906 p. digitalISSN:- 1759-7714
- Adenocarcinoma of Lung -- pathology
- Administration, Intravenous
- Carcinoma, Non-Small-Cell Lung -- pathology
- Carcinoma, Squamous Cell -- pathology
- Chemoradiotherapy -- mortality
- Endostatins -- administration & dosage
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms -- pathology
- Male
- Middle Aged
- Patient Safety
- Prognosis
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.